Genetic and genomic predictors of anti-TNF response

Rita Prajapati, Darren Plant, Anne Barton

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The introduction of anti-TNF therapy has dramatically improved the outlook for patients suffering from a number of inflammatory conditions including rheumatoid arthritis and inflammatory bowel disease. Despite this, a substantial proportion of patients (approximately 30-40%) fail to respond to these potentially toxic and expensive therapies. Treatment response is likely to be multifactorial; however, variation in genes or their expression may identify those most likely to respond. By targeted testing of variants within candidate genes, potential predictors of anti-TNF response have been reported; however, very few markers have replicated consistently between studies. Emerging genome-wide association studies suggest that there may be a number of genes with modest effects on treatment response rather than a few genes of large effect. Other potential serum biomarkers of response have also been explored including cytokines and autoantibodies, with antibodies developing to the anti-TNF drugs themselves being correlated with treatment failure. © 2011 Future Medicine Ltd.
    Original languageEnglish
    Pages (from-to)1571-1585
    Number of pages14
    JournalPharmacogenomics
    Volume12
    Issue number11
    DOIs
    Publication statusPublished - Nov 2011

    Keywords

    • anti-TNF
    • anti-TNF response
    • Crohns disease
    • gene expression
    • genetic
    • genomic
    • rheumatoid arthritis
    • serum biomarkers
    • ulcerative colitis

    Fingerprint

    Dive into the research topics of 'Genetic and genomic predictors of anti-TNF response'. Together they form a unique fingerprint.

    Cite this